Your one-stop source of market and regulatory strategic data for the CBD industry
Start your FREE trial now
CBD-Intel provides premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sector worldwide.
We provide our clients with the tools to navigate this fast-moving sector, tailor their business strategy, optimise resources and make informed decisions. We offer a wide range of services from long term subscription plans, individual reports available for purchase, customised research and consultancy support.
Providing all the data in one online platform reduces the amount of time and money spent monitoring the sector for multiple international markets.
Our global perspective on the international CBD sector offers you key data such as market trends, key players, regulatory obligations and industry dynamics. You will also have access to:
CBD-Intel’s team is made up by a leading group of lawyers, economists and journalists. The team is based between London, Barcelona and Washington DC, along with correspondents and contributors from around the world.
We are wholly independent of the sector, giving you access to frank and objective analysis that may not be available to other industry participants.
CBD as a Novel Food: the future for edibles in Europe
This new CBD-Intel report examines key aspects and drivers of the edibles market itself before looking in detail at the Novel Food regulations, both at EU level and in non-EU markets: notably the UK, as well as Switzerland and Norway.
Questions it considers and answers include whether CBD really is novel, whether approvals are likely to be generic or applicant-specific, how the Novel Food Catalogue and RASFF operate, and the costs of Novel Food applications.
This report also includes a 1-hour consultation call with CBD-Intel’s analyst team.
Free sample available
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.